Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression

References

• Ferlay J , Soerjomataram I , Dikshit R , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer . 2015;136(5):E359–E386. doi:10.1002/ijc.29210 25220842
   PubMed Web of Science ®Google Scholar
• Forner A , Gilabert M , Bruix J , et al. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol . 2014;11(9):525–535. doi:10.1038/nrclinonc.2014.122 25091611
   PubMed Web of Science ®Google Scholar
• Han G , Berhane S , Toyoda H , et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology . 2020;72(1):198–212. doi:10.1002/hep.31022 31698504
   PubMed Web of Science ®Google Scholar
• Sanoff HK , Chang Y , Lund JL , et al. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist . 2016;21:1113–1120. doi:10.1634/theoncologist.2015-0478 27185615
   PubMed Web of Science ®Google Scholar
• Wang C , Wang H , Yang W , et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology . 2015;61:1579–1590. doi:10.1002/hep.27548 25284802
   PubMed Web of Science ®Google Scholar
• Loustaud-Ratti V , Debette-Gratien M , Carrier P . European association for the study of the liver and French hepatitis C recent guidelines: the paradigm shift. World J Hepatol . 2018;10:639–644. doi:10.4254/wjh.v10.i10.639 30386457
   PubMed Web of Science ®Google Scholar
• Heimbach JK , Kulik LM , Finn RS , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology . 2018;67:358–380. doi:10.1002/hep.29086 28130846
   PubMed Web of Science ®Google Scholar
• Omata M , Cheng AL , Kokudo N , et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int . 2017;11:317–370.28620797
   PubMed Web of Science ®Google Scholar
• Kudo M , Trevisani F , Abou-Alfa GK , et al. Hepatocellular carcinoma: therapeutic guidelines and medical treatment. Liver Cancer . 2016;6:16–26. doi:10.1159/000449343 27995084
   PubMed Web of Science ®Google Scholar
• Marrero JA , Kulik LM , Sirlin CB , et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology . 2018;68:723–750. doi:10.1002/hep.29913 29624699
   PubMed Web of Science ®Google Scholar
• Llovet JM , Bruix J . Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology . 2003;37:429–442. doi:10.1053/jhep.2003.50047 12540794
   PubMed Web of Science ®Google Scholar
• Sun J , Shi J , Huang B , et al. The degree of hepatic arterial blood supply of portal vein tumor thrombus in patients with hepatocellular carcinoma and its impact on overall survival after transarterial chemoembolization. Oncotarget . 2017;8:79816–79824. doi:10.18632/oncotarget.19767 29108363
   PubMedGoogle Scholar
• Lencioni R . Loco-regional treatment of hepatocellular carcinoma. Hepatology . 2010;52:762–773. doi:10.1002/hep.23725 20564355
   PubMed Web of Science ®Google Scholar
• Li X , Feng GS , Zheng CS , et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol . 2004;10:2878–2882. doi:10.3748/wjg.v10.i19.2878 15334691
   PubMed Web of Science ®Google Scholar
• Sergio A , Cristofori C , Cardin R , et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol . 2008;103:914–921. doi:10.1111/j.1572-0241.2007.01712.x 18177453
   PubMed Web of Science ®Google Scholar
• Dufour JF , Johnson P . Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol . 2010;52:296–304. doi:10.1016/j.jhep.2009.11.010 20006399
   PubMedGoogle Scholar
• Llovet JM , Ricci S , Mazzaferro V , et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med . 2008;359:378–390. doi:10.1056/NEJMoa0708857 18650514
   PubMed Web of Science ®Google Scholar
• Jackson R , Psarelli EE , Berhane S , et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized Phase III trials. J Clin Oncol . 2017;35:622–628. doi:10.1200/JCO.2016.69.5197 28045619
   PubMed Web of Science ®Google Scholar
• Pinter M , Hucke F , Graziadei I , et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology . 2012;263:590–599. doi:10.1148/radiol.12111550 22438359
   PubMed Web of Science ®Google Scholar
• Kudo M , Imanaka K , Chida N , et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer . 2011;47:2117–2127. doi:10.1016/j.ejca.2011.05.007 21664811
   PubMed Web of Science ®Google Scholar
• Lencioni R , Llovet JM , Han G , et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol . 2016;64:1090–1098. doi:10.1016/j.jhep.2016.01.012 26809111
   PubMed Web of Science ®Google Scholar
• Meyer T , Fox R , Ma YT , et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo controlled, double-blind, Phase 3 trial. Lancet Gastroenterol Hepatol . 2017;2(8):565–575. doi:10.1016/S2468-1253(17)30156-5 28648803
   PubMed Web of Science ®Google Scholar
• Kudo M , Ueshima K , Ikeda M , et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut . 2019;69(8):1492–1501. doi:10.1136/gutjnl-2019-318934 31801872
   PubMed Web of Science ®Google Scholar
• Park JW , Kim YJ , Kim DY , et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol . 2019;70(4):684–691. doi:10.1016/j.jhep.2018.11.029 30529387
   PubMed Web of Science ®Google Scholar
• Han K , Kim JH , Ko GY , et al. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review. World J Gastroenterol . 2016;22:407–416. doi:10.3748/wjg.v22.i1.407 26755886
   PubMed Web of Science ®Google Scholar
• Wilhelm SM , Adnane L , Newell P , et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther . 2008;7:3129–3140. doi:10.1158/1535-7163.MCT-08-0013 18852116
   PubMed Web of Science ®Google Scholar
• Tsuchida Y , Therasse P . Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol . 2001;37:1–3. doi:10.1002/mpo.1154 11466715
   PubMedGoogle Scholar
• Lencioni R , Llovet JM . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis . 2010;30:52–60. doi:10.1055/s-0030-1247132 20175033
   PubMed Web of Science ®Google Scholar
• Gillmore R , Stuart S , Kirkwood A , et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol . 2011;55:1309–1316. doi:10.1016/j.jhep.2011.03.007 21703196
   PubMed Web of Science ®Google Scholar
• Tovoli F , Renzulli M , Granito A , et al. Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. Hepat Oncol . 2017;4:129–137. doi:10.2217/hep-2017-0018 30191059
   PubMed Web of Science ®Google Scholar
• Park JW , Park KW , Cho SH , et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol . 2005;100:2194–2200. doi:10.1111/j.1572-0241.2005.00232.x 16181368
   PubMed Web of Science ®Google Scholar
• Renzulli M , Peta G , Vasuri F , et al. Standardization of conventional chemoembolization for hepatocellular carcinoma. Ann Hepatol . 2020;22:100278. doi:10.1016/j.aohep.2020.10.006 33129978
   PubMed Web of Science ®Google Scholar
• Prajapati HJ , Xing M , Spivey JR , et al. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. AJR Am J Roentgenol . 2014;203(6):W706–W714. doi:10.2214/AJR.13.12308 25415737
   PubMed Web of Science ®Google Scholar
• Vasuri F , Golfieri R , Fiorentino M , et al. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. Virchows Archiv . 2011;459(2):141–146. doi:10.1007/s00428-011-1099-5 21691816
   PubMed Web of Science ®Google Scholar
• Cheng AL , Kang YK , Chen Z , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol . 2009;10:25–34. doi:10.1016/S1470-2045(08)70285-7 19095497
   PubMed Web of Science ®Google Scholar
• Forner A , Reig ME , Bruix J , et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis . 2010;30:61–74. doi:10.1055/s-0030-1247133 20175034
   PubMed Web of Science ®Google Scholar
• Hiraoka A , Kumada T , Kudo M , et al. Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis. Dig Dis Sci . 2017;35:602–610. doi:10.1159/000480256
   Web of Science ®Google Scholar
• Liu L , Zhang C , Zhao Y , et al. Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. Biomed Res Int . 2014;2014:194278.24800212
   PubMed Web of Science ®Google Scholar
• Varela M , Real MI , Burrel M , et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol . 2007;46(3):474–481. doi:10.1016/j.jhep.2006.10.020 17239480
   PubMed Web of Science ®Google Scholar
• Lencioni R , Petruzzi P , Crocetti L . Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol . 2013;30(1):3–11. doi:10.1055/s-0033-1333648 24436512
   PubMed Web of Science ®Google Scholar
• Cucchetti A , Trevisani F , Cappelli A , et al. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis . 2016;48:798–805. doi:10.1016/j.dld.2016.03.031 27263056
   PubMedGoogle Scholar
• Compagnone G , Giampalma E , Domenichelli S , et al. Calculation of conversion factors for effective dose for various interventional radiology procedures. Med Phys . 2012;39(5):2491–2498. doi:10.1118/1.3702457 22559619
   PubMed Web of Science ®Google Scholar
• Zhao Y , Wang WJ , Guan S , et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol . 2013;24:1786–1792. doi:10.1093/annonc/mdt072 23508822
   PubMed Web of Science ®Google Scholar
• Chao Y , Chung YH , Han G , et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer . 2015;136:1458–1467. doi:10.1002/ijc.29126 25099027
   PubMed Web of Science ®Google Scholar
• Wilhelm SM , Carter C , Tang L , et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res . 2004;64:7099–7109. doi:10.1158/0008-5472.CAN-04-1443 15466206
   PubMed Web of Science ®Google Scholar
• Strumberg D . Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today . 2005;41:773–784. doi:10.1358/dot.2005.41.12.937959
   PubMed Web of Science ®Google Scholar
• Carmeliet P , Jain RK . Angiogenesis in cancer and other diseases. Nature . 2000;407:249–257. doi:10.1038/35025220 11001068
   PubMed Web of Science ®Google Scholar
• Wang B , Xu H , Gao ZQ , et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol . 2008;49:523–529. doi:10.1080/02841850801958890 18568538
   PubMed Web of Science ®Google Scholar
• Facciorusso A , Bellanti F , Villani R , et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United European Gastroenterol J . 2017;5(4):511–518. doi:10.1177/2050640616673516
   PubMed Web of Science ®Google Scholar
• Facciorusso A , Licinio R , Muscatiello N , et al. Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol . 2015;7:2009–2019. doi:10.4254/wjh.v7.i16.2009 26261690
   PubMedGoogle Scholar
• Facciorusso A , Serviddio G , Muscatiello N . Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: a systematic review and meta-analysis. World J Hepatol . 2016;8(18):770–778. doi:10.4254/wjh.v8.i18.770 27366304
   PubMedGoogle Scholar
• Wu FX , Chen J , Bai T , et al. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer . 2017;17(1):645. doi:10.1186/s12885-017-3545-5 28899349
   PubMed Web of Science ®Google Scholar
• Ren B , Wang W , Shen J , et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE alone for unresectable hepatocellular carcinoma: a propensity score matching study. J Cancer . 2019;10(5):1189–1196. doi:10.7150/jca.28994 30854128
   PubMed Web of Science ®Google Scholar
• Bruix J , Reig M , Rimola J , et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology . 2011;54:2238–2244. doi:10.1002/hep.24670 21932394
   PubMed Web of Science ®Google Scholar
• Llovet JM , Brú C , Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis . 1999;19:329–338. doi:10.1055/s-2007-1007122 10518312
   PubMed Web of Science ®Google Scholar
• Bolondi L , Burroughs A , Dufour JF , et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis . 2012;32:348–359. doi:10.1055/s-0032-1329906 23397536
   PubMed Web of Science ®Google Scholar
• Giannini EG , Moscatelli A , Pellegatta G , et al. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma. Am J Gastroenterol . 2016;111(1):70–77. doi:10.1038/ajg.2015.389 26729544
   PubMed Web of Science ®Google Scholar
• Facciorusso A . The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. Curr Diabetes Rev . 2013;9(5):382–386. doi:10.2174/15733998113099990068 23845075
   PubMedGoogle Scholar
• Raoul JL , Sangro B , Forner A , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev . 2011;37:212–220. doi:10.1016/j.ctrv.2010.07.006 20724077
   PubMed Web of Science ®Google Scholar
• Strebel BM , Dufour JF . Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther . 2008;8:1743–1749. doi:10.1586/14737140.8.11.1743 18983234
   PubMed Web of Science ®Google Scholar
• Park JW , Koh YH , Kim HB , et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol . 2012;56:1336–1342. doi:10.1016/j.jhep.2012.01.006 22314421
   PubMed Web of Science ®Google Scholar
• Ogasawara S , Chiba T , Ooka Y , et al. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs . 2018;36:332–339. doi:10.1007/s10637-017-0507-3 28891038
   PubMed Web of Science ®Google Scholar
• Jun BG , Kim YD , Kim SG , et al. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: a multicenter study. PLoS One . 2018;13:e0201316. doi:10.1371/journal.pone.0201316 30059513
   PubMed Web of Science ®Google Scholar
• Lin XJ , Lao XM , Shi M , et al. Changes of HBV DNA after chemoembolization for hepatocellular carcinoma and the efficacy of antiviral treatment. Dig Dis Sci . 2016;61:2465–2476. doi:10.1007/s10620-016-4167-5 27105647
   PubMed Web of Science ®Google Scholar
• Wang K , Jiang G , Jia Z , et al. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative. Medicine . 2018;97:e10940. doi:10.1097/MD.0000000000010940 29851833
   PubMed Web of Science ®Google Scholar
• Yuan J , Yin X , Tang B , et al. Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Biomed Res Int . 2019;2019:2141859. doi:10.1155/2019/2141859 31467872
   PubMed Web of Science ®Google Scholar
• Yip B , Wantuck JM , Kim LH , et al. Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci . 2014;59:192–200. doi:10.1007/s10620-013-2948-7 24282055
   PubMed Web of Science ®Google Scholar
• Guarino M , Sessa A , Cossiga V , et al. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows. World J Gastroenterol . 2018;24(24):2582–2595. doi:10.3748/wjg.v24.i24.2582 29962815
   PubMed Web of Science ®Google Scholar
• Abbas Z , Siddiqui AU , Luck NH , et al. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. J Pak Med Assoc . 2008;58(11):602–607.19024130
   PubMedGoogle Scholar
• Marasco G , Serenari M , Renzulli M , et al. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. J Gastroenterol . 2020;55(10):927–943. doi:10.1007/s00535-020-01711-w 32748172
   PubMed Web of Science ®Google Scholar